期刊文献+

重组人白细胞介素3对环磷酰胺所致犬造血损伤的治疗作用 被引量:2

Therapeutic effect of rhIL-3 on hematopoietic depression in dogs induced by cyclophosphamide
下载PDF
导出
摘要 白细胞介素3(interleukin-3,IL-3)又称多集落刺激因子(multi-colony stimulating factor),是作用于较早期阶段的具有广谱效应的造血刺激因子,对恶性贫血、再生障碍性贫血、骨髓增生异常综合征(MDS)以及各种继发性造血功能障碍疾病有显著疗效。本实验建立环磷酸胺(Cy)致家犬造血抑制的动物模型,用rhIL-3和碳酸锂(LC)进行对比研究,阐明rhIL-3的疗效、作用机理及毒副作用,为进一步研制和应用IL-3提供依据。 Cyclophosphamide (Cy) could decrease the number of peripheral WBC and induce the hematopoiesis depression in dogs. In this study, different doses of rhIL-3 were administrated subcutaneously to the Cy-treated dogs for seven days, and the changes of symptoms and general conditions, peripheral blood cells and bone marrow cells were observed in treated dogs. The results showed that, after rhIL-3 treated, the general conditions improved dramatically, the decreasing degree of the peripheral WBC which was caused by using Cy was alleviated obviously and the duration of low-number WBC (lower than 50% of normal value) was shortened. It was also demonstrated that the bone marrow CFU-GM, CFU-E and BFU-E were promoted, the total number of bone marrow nucleated cell and the counts of platelet and reticulocyte were higher than PBS control group. These effects of rhIL-3 were more obviously in large dose group. It is suggested that rhIL-3 has a strong promoting effects on hematopoiesis and could be used in treatment of hematopoiesis depression especially in the patients using Cy to cure cancer.
出处 《中国实验血液学杂志》 CAS CSCD 1998年第4期304-306,共3页 Journal of Experimental Hematology
关键词 重组人白细胞介素3 环磷酰胺 白细胞减少 造血 rhIL-3 cyclophosphamide leucopenia hematopoiesis
  • 相关文献

同被引文献13

  • 1-.新药(西药)临床前研究指导原则汇编(药学药理毒理学)[M].中华人民共和国卫生部药政局,1993.199-201.
  • 2Shim MH, Hoover A, Blake N, et al. Gene expression profile of primary human CD34+ CD38 low cells differentiating along the megakaryocyte lineage [J]. Exp Hematol,2004,32(7) : 638.
  • 3Proulx C,Boyer L, Hurnanen DR,et al. Preferential ex vivo expansion of megakaryocytes from human cord blood CD34+-enriched cells in the presence of thrombopoietin and limiting amounts of stem cell factor and Flt-3 ligand[J]. J Hematother Stem Cell Res,2003,12(2) : 179.
  • 4Van-Geet C. Thrombopoiesis: new concepts [J]. Verh K Acad Geneeskd Belg,2004,66(1) : 5.
  • 5Italiano, Joseph EJ,Lecine P,et al. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes[J]. J Cell Biol, 1999,147(6) : 1299.
  • 6Yang C, Xia Y, Li J, et al. The appearance of anti-thrombopoietin antibody and circulating thrombopoietin-IgG complexes in a patient developing thrombocytopenia afte rthe injection of PEG-rHuMGDF[J]. Blood, 1999,94:681.
  • 7Andrews RG, Winkler A, Mvern D, et al. Recombinant human ligand for MPL,megakaryocyte growth and development faetor(MGDF), stimulates thrombopoisis in vivo in normal and myelosuppressed bauoons[J]. Stem Cells,1996,14:661.
  • 8Zweegman S, Van DBJ, Mus AM, et al. Bone marrow stromal proteoglycans regulate megakaryocytic differentiation of human progenitor cells[J]. Exp Cell Res, 2004,299(2) : 383.
  • 9Rubin CI, French DL, Atweh GF. Stathmin expression and megakaryocyte differentiation., a potential role in polyploidy[J] Exp Hematol,2003,31(5) : 389.
  • 10Fujimoto TT, Kohata S, Suzuki H, et al. Production of functional platelets by differentiated embryonic stem(ES) cells in vitro[J]. Blood, 2003,102(12) : 4044.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部